A murine model of enterohemorrhagic Escherichia coli O157:H7 infection to assess immunopotentiating activity of drugs on mucosal immunity: effect of drugs.
An enterohemorrhagic Escherichia coli (EHEC) O157 oral infection murine model was established to examine the potentiating activity of drugs on mucosal immune responses. Groups of ICR mice inoculated intragastrically with 10(11) CFU/kg EHEC O157 showed chronic intestinal infection with the pathogen that persisted over 3 weeks and resulted in the synthesis of relatively high levels of antigen specific fecal IgA antibody. Intraperitoneal administration of 80 NU/kg Neurotropin, an immunopotentiator, augmented the antigen specific mucosal immune responses to EHEC O157. On the other hand, FK506 clearly suppressed the response. To further document the augmenting effect of Neurotropin on mucosal immune responses, mice were immunized intranasally with a mixture of ovalbumin and cholera toxin. Co-administration of 80 NU/kg Neurotropin significantly potentiated the synthesis of fecal IgA and serum IgG antibodies. These results suggest that Neurotropin has potential as a mucosal adjuvant to promote secretory IgA antibody production and that the mice model of oral infection with EHEC O157 is useful for immunopharmacological studies of bacterial infection-defensive mucosal immune responses.
Nagano
Keiji
K
Laboratory of Microbiology, Department of Public Health Pharmacy, Gifu Pharmaceutical University, Japan. morih@gifu-pu.ac.jp
Sugisaki
Takeshi
T
Taguchi
Kazuki
K
Hara
Takumi
T
Naiki
Mitsuru
M
Mori
Hiroshi
H
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology*; D000281:Administration, Intranasal; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis / Q000097:blood; D000917:Antibody Formation / Q000187:drug effects; D004195:Disease Models, Animal; D004768:Enterotoxins / Q000008:administration & dosage / Q000276:immunology; D004927:Escherichia coli Infections / Q000276:immunology* / Q000382:microbiology; D019453:Escherichia coli O157 / Q000276:immunology*; D005243:Feces / Q000382:microbiology; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects / Q000276:immunology; D018928:Immunity, Mucosal / Q000187:drug effects*; D007070:Immunoglobulin A / Q000096:biosynthesis; D007074:Immunoglobulin G / Q000096:biosynthesis; D007274:Injections, Intraperitoneal; D051379:Mice; D008813:Mice, Inbred ICR; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology; D011134:Polysaccharides / Q000008:administration & dosage / Q000494:pharmacology*; D016559:Tacrolimus / Q000008:administration & dosage / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D004768:Enterotoxins; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D011134:Polysaccharides; C037420:stN protein, Vibrio cholerae; C010491:neurotropin; D010047:Ovalbumin; D016559:Tacrolimus